Identifying those "at risk" of Parkinson's disease (PD) is a priority and a key strategy for testing neuroprotective agents. 1 PREDICT-PD is a pilot cohort study in which healthy UK adults are screened online (www.predictpd.com) with a questionnaire that ascertains the presence of early phenotypic features and risk factors, based on systematic review. 2 Subjects are ascribed risk scores according to their answers and then complete additional online tests. 3 Higherrisk and lower-risk subjects are compared by using various markers for PD and eventual clinical outcome. We hypothesized that if risk stratification were effective in 1,319 eligible participants, an excess of GBA variants and LRRK2 mutations would be found in higher-risk subjects compared with lower-risk (inclusion and exclusion criteria and risk scoring have been previously described 3 ). A greater likelihood of identifying differences in outcomes was anticipated if extremes of risk were sampled. Risk scores were ranked to enable comparative analyses between subjects with the highest 15% and lowest 15% risk scores. Invitations were extended to these subjects, and additional subjects sampled randomly from the middle-risk group, to participate with inperson clinical studies (see Supplemental Data Table for sampling and acceptance rates).
Sanger sequencing was performed on DNA extracted from the saliva of 192 subjects to screen exon 41 of LRRK2 (which contains the commonest c.6055 G>A; p.G2019S mutation) and exons 8-11 of the GBA gene (contains almost 90% of recognized GBA pathogenic variants).
4 GBA variants were found in 6 of 75 higher-(1 N370S, 2 E326K, 3 T369M), 0 of 43 middle-, and 1 of 67 lower-risk subjects (T369M homozygous) (see Table 1 ). The odds ratio of having a GBA variant in the higher-versus the pooled middleand lower-risk groups was 9.48 (95% confidence interval, 1.12-80.47; P 5 0.018). LRRK2 G2019S mutations were not found in any participant.
Of the variants identified, N370S has a deleterious effect on glucocerebrosidase enzyme activity and is known to cause Gaucher's disease, as well as being a clear risk factor for PD. E326K and T369M are functionally mild variants, not severe enough to cause Gaucher's disease even when present in the homozygous/compound heterozygous state. 5, 6 Nonetheless, our results add to the notion that both E326K and T369M may, in the right milieu of genetic and environmental factors, contribute to the risk of PD.
4,5 Failure to find LRRK2 mutations was unsurprising given the rarity of the G2019S mutation in healthy controls and its presence in only 1% to 2% of patients with PD.
7 GBA variants were found in 8% of higher-risk subjects, a proportion similar to estimates of frequency in sporadic PD. 4 Conversely, less than 1% of lower-risk subjects were found to have a GBA variant. An overall rate of 3.6% in the total sample was observed, which is similar to the 4% reported in healthy controls. 5 Age is a powerful determinant of PD risk but has the potential to confound given its effect on many outcome measures used in predictive studies (eg, sense of smell, objective motor function, and functional imaging). By using GBA variants as an outcome for risk stratification, age-independent support for enrichment was observed. - 
Supporting Data
Additional Supporting Information may be found in the online version of this article.
Adaptive Deep Brain Stimulation in a Freely Moving Parkinsonian Patient
The future of deep brain stimulation (DBS) for Parkinson's disease (PD) lies in new closed-loop systems that continuously supply the implanted stimulator with new settings obtained by analyzing a feedback signal related to the patient's current clinical condition. 1 The most suitable feedback for PD is subthalamic local field potential (LFP) activity recorded from the stimulating electrode itself. [2] [3] [4] This closed-loop technology known as adaptive DBS (aDBS) recently proved superior to conventional open-loop DBS (cDBS) in patients with PD. 2 No studies have yet tested aDBS in freely moving humans for a prolonged time. This information is an essential prerequisite for developing new implantable aDBS devices for chronic PD treatment.
In this single-case study, we tested whether a portable DBS device we developed is suitable to compare the clinical benefit in a freely moving PD patient induced by either aDBS or cDBS. To do so, after a first experimental session for extracting patient settings to personalize the aDBS algorithm, we treated a blinded patient (51 y old, male, 8 y PD history) with cDBS and aDBS in two separate experimental sessions each lasting 120 min, 5 and 6 d, respectively, after DBS electrode implant. To ensure reliable results, the patient underwent repeated clinical assessments every 20 min (T1-T5) by two independent blinded neurologists through Unified Parkinson's Disease Rating Scale (UPDRS) III subsections and Rush Dyskinesia Rating Scale (see Supplemental Data for details).
The aDBS portable device we used was equipped with an ad hoc algorithm that analyzed patient's LFP beta band power (13-17 Hz) and adapted voltage stimulation linearly each second (Fig. 1A) .
The patient during aDBS experienced a more stable condition than during cDBS, with better control of symptoms and dyskinesias over time ( Fig. 1; video 1 ). In particular, aDBS and cDBS improved patient's axial symptoms to a similar extent (Fig. 1B) , but compared with cDBS, aDBS significantly improved his main symptom, bradykinesia (Fig. 1C) . aDBS did not elicit side effects and was well tolerated.
Because we evaluated the patient a few days after surgery when he probably manifested a stunning effect, 5 the aDBSand cDBS-induced improvements were lower than those reported by others in follow-up DBS studies. 6 A major clinical achievement was that compared with cDBS, aDBS greatly reduced the patient's dyskinesias during gait and at rest ( Fig. 1B; Fig. 1D ). Presumably it did so because we designed the adaptive algorithm to avoid dyskinesias related to hyperstimulation: when L-dopa reduced beta-band LFP activity, the voltage linearly diminished, avoiding hyperstimulation. Full financial disclosures and author roles may be found in the online version of this article.
